Sentence examples for lymph node assay from inspiring English sources
The mouse local lymph node assay (LLNA; OECD TG 429) is one example.
In contrast, the mouse local lymph node assay does include dose response assessment and is appropriate for this purpose.
In addition, we also evaluated the skin sensitization potential of nanoparticles using a local lymph node assay with incorporation of BrdU.
With this testing strategy, a correlation with human skin sensitizers is obtained, which is slightly better than that obtained in the local lymph node assay (LLNA) [66, 67].
The local lymph node assay using 5-bromo-2-deoxyuridine (BrdU) with flow cytometry (LLNA: BrdU-FCM) is a modified LLNA that is used to identify skin sensitizers by counting BrdU-incorporated lymph node cells (LNCs) with flow cytometry.
We compared the recently FDA-approved Veridex GeneSearch��� Breast Lymph Node (BLN) Assay (Veridex, LLC; Warren, NJ), a real time reverse transcriptase-polymerase chain reaction assay that is designed to detect metastases > 0.2 mm, with our standard lymph node processing.
The OECD test guidelines 406 recommend the use of 30 guinea pigs for the Guinea Pig Maximisation Test or the Buehler Test [4], whilst OECD test guidelines 429 recommend the use of 25 mice for the local lymph node (LLNA) assay, [5].
The native gp120 and the PNGaseF treated gp120 were used in a mouse lymph node overlay assay.
Recently, both hMAM and CK19 also received FDA approval as markers for the RT-PCR based analysis of SLNs in a diagnostic kit (GeneSearch Breast Lymph Node (BLN) assay; Veridex LLC, Raritan, NJ, USA).
Our results may ideally be used to develop a test that could be used during surgery to decide whether to remove inguinal LNs, similarly to the RT-PCR based, FDA-approved GeneSearch™ Breast Lymph Node (BLN) Assay (Veridex, LLC, Warren, NJ), used for the rapid intra-operative detection of sentinel LN metastases in breast cancer.
